AMINOLEBAN Amino Acids 8.0% Solution for IV Infusion 500mL
RXDRUG-DR-XY37373
Discreet Packaging
FDA-registered Products
FDA-licensed Pharmacies
Indications/Uses
Treatment of hepatic encephalopathy in patients with chronic liver disease.
Dosage/Direction for Use
The usual adult dose of Amino Acids (AMINOLEBAN) is 500-1000 mL per dose, infused via a peripheral vein. The usual peripheral infusion rate is 500 mL over 180-300 min in adults. For total parenteral nutrition, 500-1000 mL of Amino Acids (AMINOLEBAN) should be combined with glucose or other solutions and administered over 24 hours via a central vein. The dosage should be adjusted according to the patient's age, symptoms, and body weight.
Precautions: Amino Acids (AMINOLEBAN) contains about 14 mEq/L of sodium and 94 mEq/L of chloride. Concomitant use with an electrolyte solution or administration of a large dose requires careful monitoring of electrolyte balance.
Precautions: Amino Acids (AMINOLEBAN) contains about 14 mEq/L of sodium and 94 mEq/L of chloride. Concomitant use with an electrolyte solution or administration of a large dose requires careful monitoring of electrolyte balance.
Overdosage
Hyperammonemia has been reported when an amino acid solution, including Amino Acids (AMINOLEBAN), was administered in combination with oral intake of nitrogen (total nitrogen: 160 g). (See Clinically significant adverse reactions under Adverse Reactions.)
Contraindications
Amino Acids (AMINOLEBAN) is contraindicated in the following patients: Patients with serious renal disorder (patients on dialysis or hemofiltration are excluded). [Urea and other amino acid metabolites may be retained, which may worsen the patient's clinical condition.] (See Precautions.)
Patients with abnormal amino acid metabolism [Because the infused amino acids are not adequately metabolized, the patient's clinical condition may be worsened.]
Patients with abnormal amino acid metabolism [Because the infused amino acids are not adequately metabolized, the patient's clinical condition may be worsened.]
Special Precautions
Careful Administration: Amino Acids (AMINOLEBAN) should be administered with care in the following patients: Patients with severe acidosis: The patient's clinical condition may be worsened.
Patients with congestive cardiac failure: An increase in the circulating blood volume may worsen the patient's clinical condition.
Patients on dialysis or hemofiltration with serious renal disorder: Urea and other amino acid metabolites may be retained. (See Important Precautions as follows.)
Important Precautions: The volume of urea, etc. removed and accumulated in patients on dialysis or hemofiltration with serious renal disorder varies depending on the dialysis method and patients' conditions. Initiation and continuation of administration should be determined after the patient's conditions are carefully checked based on assessment of blood biochemistry, acid-base equilibrium, and body-fluid balance, etc.
Use in the Elderly: Because elderly patients often have reduced physiological function, it is advisable to consider reducing the dose by decreasing the infusion rate.
Use in Children: The safety in children has not been established (no clinical experience).
Patients with congestive cardiac failure: An increase in the circulating blood volume may worsen the patient's clinical condition.
Patients on dialysis or hemofiltration with serious renal disorder: Urea and other amino acid metabolites may be retained. (See Important Precautions as follows.)
Important Precautions: The volume of urea, etc. removed and accumulated in patients on dialysis or hemofiltration with serious renal disorder varies depending on the dialysis method and patients' conditions. Initiation and continuation of administration should be determined after the patient's conditions are carefully checked based on assessment of blood biochemistry, acid-base equilibrium, and body-fluid balance, etc.
Use in the Elderly: Because elderly patients often have reduced physiological function, it is advisable to consider reducing the dose by decreasing the infusion rate.
Use in Children: The safety in children has not been established (no clinical experience).
Adverse Reactions
Reported incidence rates are based on data from 3324 patients with chronic liver disease, and a total of 35 patients (1.1%) experienced 52 adverse reactions (Drug Efficacy Reevaluation, March 1998, Japan).
Clinically significant adverse reactions: Hypoglycemia (frequency unknown): Hypoglycemia may occur. If the patient develops hypoglycemia, glucose should be administered promptly by intravenous infusion. In addition, appropriate nutrition management is recommended in such patients.
Hyperammonemia (frequency unknown): Hyperammonemia has been reported. If the patient develops persistent hyperammonemia during the administration of Amino Acids (AMINOLEBAN), discontinue administration of nitrogen sources including Amino Acids (AMINOLEBAN) and institute appropriate measures.
Other adverse reactions: If adverse reactions are observed, discontinue the administration, and institute appropriate treatment. (See Table 3.)
Clinically significant adverse reactions: Hypoglycemia (frequency unknown): Hypoglycemia may occur. If the patient develops hypoglycemia, glucose should be administered promptly by intravenous infusion. In addition, appropriate nutrition management is recommended in such patients.
Hyperammonemia (frequency unknown): Hyperammonemia has been reported. If the patient develops persistent hyperammonemia during the administration of Amino Acids (AMINOLEBAN), discontinue administration of nitrogen sources including Amino Acids (AMINOLEBAN) and institute appropriate measures.
Other adverse reactions: If adverse reactions are observed, discontinue the administration, and institute appropriate treatment. (See Table 3.)
Caution For Usage
Precautions Concerning Use: Before administration: To minimize the risk of infection, carry out all procedures under aseptic conditions.
In cold environmental conditions, the solution should be warmed to near body temperature before use.
Use the solution immediately after opening the container. After use, discard all unused solution.
During administration: Administer the solution slowly via a vein.
When vascular pain occurs, use an alternate site or discontinue administration.
Precautions for Handling: Crystals may precipitate in a cool place. Warm the container at 50-60°C to dissolve the precipitates and use the solution after cooling to about 37°C.
Do not remove the inner wrap until immediately before use.
Do not use the solution if the inner wrap covering the product has been damaged, or droplets of water or leakage of the content is noted, the solution is discolored or cloudy, or a precipitate that cannot be dissolved.
In cold environmental conditions, the solution should be warmed to near body temperature before use.
Use the solution immediately after opening the container. After use, discard all unused solution.
During administration: Administer the solution slowly via a vein.
When vascular pain occurs, use an alternate site or discontinue administration.
Precautions for Handling: Crystals may precipitate in a cool place. Warm the container at 50-60°C to dissolve the precipitates and use the solution after cooling to about 37°C.
Do not remove the inner wrap until immediately before use.
Do not use the solution if the inner wrap covering the product has been damaged, or droplets of water or leakage of the content is noted, the solution is discolored or cloudy, or a precipitate that cannot be dissolved.
Storage
Store at temperatures not exceeding 30°C.
Action
Pharmacology: Amino Acids (AMINOLEBAN) normalized the Fischer's ratio in the plasma and brain, improved monoamine metabolism in the brain, and corrected a sleep-wakefulness pattern in portacaval-shunted rats (chronic hepatic insufficiency model).
When infused to portacaval-shunted rats loaded with ammonia, Amino Acids (AMINOLEBAN) normalized the Fischer's ratio in the plasma and brain, decreased blood ammonia levels, and improved EEG and monoamine metabolism in the brain.
Pharmacodynamics: No available information.
Clinical Studies: Amino Acids (AMINOLEBAN) was administered to patients with hepatic encephalopathy associated with chronic liver disease, and the clinical effect of Amino Acids (AMINOLEBAN) was evaluated. A prompt improvement in the coma scale (an index of disturbance of consciousness) and a prompt decrease in blood ammonia concentrations were observed. In addition, patients showed improvement in neuropsychological function as assessed by writing, drawing, flapping tremor, number connection test, and orientation and calculation tests as well as by EEG tracings. The efficacy of Amino Acids (AMINOLEBAN) in hepatic encephalopathy in clinical studies was summarized as follows: See Table 2.
When infused to portacaval-shunted rats loaded with ammonia, Amino Acids (AMINOLEBAN) normalized the Fischer's ratio in the plasma and brain, decreased blood ammonia levels, and improved EEG and monoamine metabolism in the brain.
Pharmacodynamics: No available information.
Clinical Studies: Amino Acids (AMINOLEBAN) was administered to patients with hepatic encephalopathy associated with chronic liver disease, and the clinical effect of Amino Acids (AMINOLEBAN) was evaluated. A prompt improvement in the coma scale (an index of disturbance of consciousness) and a prompt decrease in blood ammonia concentrations were observed. In addition, patients showed improvement in neuropsychological function as assessed by writing, drawing, flapping tremor, number connection test, and orientation and calculation tests as well as by EEG tracings. The efficacy of Amino Acids (AMINOLEBAN) in hepatic encephalopathy in clinical studies was summarized as follows: See Table 2.
Pharmacokinetics: (Reference data in rats): 14C-labeled amino acids formulated in Amino Acids (AMINOLEBAN) were readily distributed to almost the entire body after intravenous infusion in rats. In 6 hours, 50 to 70% of the administered amino acids was taken up into protein fractions. The ratio of branched-chain amino acids to the total amino acids in the protein fractions was highest in the brain. Up to 72 hr, 41.7% of the administered dose was excreted in the expired air, 5.9% in the urine, and 2.6% in the feces.
MedsGo Class
Parenteral Nutritional Products
Features
Brand
Aminoleban
Full Details
Dosage Strength
8% w/v
Drug Ingredients
- Amino Acid
Drug Packaging
Solution for Infusion (I.V.) 500ml
Generic Name
Amino Acid
Dosage Form
Solution for Infusion (I.V.)
Registration Number
DR-XY37373
Drug Classification
Prescription Drug (RX)
Please sign in so that we can notify you about a reply